Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human papillomavirus recombinant vaccine nonavalent - Xiamen Innovax Biotech

Next Previous
Drug Profile

Human papillomavirus recombinant vaccine nonavalent - Xiamen Innovax Biotech

Alternative Names: Human papillomavirus recombinant vaccine 9-valent - Xiamen Innovax Biotech; Human papillomavirus recombinant vaccine multivalent - Xiamen Innovax Biotech; Nonavalent HPV vaccine - Xiamen Innovax Biotech; Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.coli) - Xiamen Innovax Biotech; Recombinant human papillomavirus vaccine (6,11,16,18,31,33,45,52,58 type) - Xiamen Innovax Biotech

Latest Information Update: 30 Jun 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xiamen Innovax Biotech
  • Developer Beijing Wantai Bio-pharm; Xiamen Innovax Biotech; Xiamen University
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cervical cancer; Condylomata acuminata

Most Recent Events

  • 25 Jul 2022 Xiamen University, Xiamen Innovax Biotech and Beijing Wantai Bio-pharm completes a phase III trial for Cervical cancer and Condylomata acuminata (Prevention) in China (IM) (NCT04782895)
  • 19 Sep 2021 Xiamen University, Xiamen Innovax Biotech and Beijing Wantai Biological Pharmacy initiates enrolment in a phase III trial for Cervical Cancer and Condylomata Acuminata (Prevention) in China (IM) (NCT05056402) .
  • 08 Apr 2021 Xiamen University, Xiamen Innovax Biotech and Beijing Wantai Bio-pharm completes enrolment in its phase III trial for Cervical cancer and Condylomata acuminata (Prevention) in China (IM) (NCT04782895)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top